CADL

4.9703.12%
PT

Paul-Peter Tak

President, CEO & Director

Dr. Paul-Peter Tak, M.D. PH.D. FMEDSCI, has been Member of Advisory Board at SecondWave Systems, Inc. from March 2024. He serves as President & Chief Executive Officer at Candel Therapeutics, Inc. since September 2020 and serves as its Director since September 2020. He has been Non-Executive Director at Citryll BV and serves as its Chairman of the Board of Director. He serves as Member of Scientific Advisory Board at LifeVault Bio Inc. since 2022. He served as a Venture Partner at Flagship Pioneering. He serves as Scientific Founder & Director at Sitryx Therapeutics. He was Chief Immunology Officer and Senior Vice President of Research and Development at GlaxoSmithKline. He serves as the Scientific Founder and Independent Director at Sitryx Therapeutics Limited. He has career in the life sciences, Paul-Peter has created and led multiple companies. Dr. Tak served as Senior Vice President of R&D Pipeline at GlaxoSmithKline since January 2016. He was CEO and board member of Tempero Pharmaceuticals (Cambridge, MA) from 2012 until 2015, at which point he facilitated the company's acquisition by GSK. Dr. Tak served as Senior Vice President and Head of Immunoinflammation Therapy Area Unit at GlaxoSmithKline plc since 2011. From 2011 until 2017, Paul-Peter founded and served as senior vice president and head of the immune-inflammation therapy area unit at GSK. Under Paul-Peter's leadership, this unit brought more than 10 new mechanisms of action into the clinic and filed Benlysta s.c. which has been approved for the treatment of SLE. Dr. Tak was a Scientist at the University of California San Diego for two years. He served as a Professor of Medicine and Chairman of the Department of Clinical Immunology and Rheumatology at the Academic Medical Centre/University of Amsterdam (AMC) for 12 years. In addition to his work in academia he established a biotech company in developing intra-articular gene therapy (Arthrogen b.v.). He serves as Co-Chairman of the Technology Investment Board, Member of the Portfolio Investment Board and Member of the Bioelectronics Investment Board. He is a fellow of the Academy of Medical Sciences in the U.K. Dr. Tak serves as a Member of Scientific Advisory Board at Index Life VI. He served as a Director of ViiV Healthcare Limited. He serves on several company and editorial boards. He is a co-founder and board member of Sitryx Therapeutics (Oxford, UK). He is a current board member of Levicept. He is a member of the editorial board at Current Biotechnology and was previously the co-editor of Arthritis & Rheumatology. He serves as a member of the Innovation Board Steering Committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA). Dr. Tak received his Medical Degree cum laude from the Free University in Amsterdam and was trained as an internist, rheumatologist and immunologist at Leiden University Medical Center, where he also received his PhD. He has been Clinical Associate Professor of Medicine at the University of California San Diego. He has published extensively in peer-reviewed journals and received numerous awards. He was the Chair of the Scientific Review Board, the governing body accountable for the scientific assessment of GSK’s R&D portfolio. Dr. Tak served as President and CEO of Kintai Therapeutics, a start-up focused on enteric signaling networks, where he oversaw the creation of a portfolio of proprietary small molecules called precision enteric medicines for the treatment of obesity, neurological disease and cancer. In addition, he has served as Board Member of Galvani Bioelectronics, Omega Therapeutics and Citryll.

Positions